Affymax, Inc.  

(Public, OTCMKTS:AFFY)   Watch this stock  
Find more results for AFFY
0.000 (0.00%)
Jul 31 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.10 - 0.10
52 week 0.09 - 2.03
Open 0.10
Vol / Avg. 83,644.00/684,585.00
Mkt cap 3.75M
P/E 0.35
Div/yield     -
EPS 0.29
Shares 37.49M
Beta 1.94
Inst. own 2%

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -1053.62%
Operating margin - -1099.05%
EBITD margin - -2724.25%
Return on average assets -80.30% -22.96%
Return on average equity - -420.95%
Employees 4 -
CDP Score - -


Suite 240, 19200 Stevens Creek Blvd
United States - Map
+1-650-8128700 (Phone)
+1-650-4240832 (Fax)

Website links


Affymax, Inc. is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, peginesatide, is for the treatment of anemia in chronic kidney disease patients on dialysis. Peginesatide is a synthetic peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a worldwide collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited (Takeda). As of December 31, 2011, over 2,600 patients have received peginesatide in clinical trials. As of December 31, 2011, The New Drug Application (NDA) for peginesatide is under review by the United States, Food and Drug Administration (FDA). As of December 31, 2011, the Company has suspended its development efforts to treat anemia in non-dialysis patients and chemotherapy-induced anemia.

Officers and directors

John A. Orwin Chairman of the Board
Age: 49
J. Weston Rose President
Age: 63
Richard M. Brenner Chief Executive Officer, Director
Age: 63
Mark Thompson Chief Financial Officer
Age: 52
Karin L. Walker CPA., Chief Accounting Officer, Vice President - Finance
Age: 40
Tim Varacek Vice President - Sales and Account Management
Christine R. Conroy Vice President - Regulatory Affairs and Clinical Quality Assurance
Age: 52
Michael Holfinger Ph.D. Vice President - Manufacturing and CMC Development
Age: 49
Grace U. Shin General Counsel
Age: 48
Anne-Marie Duliege M.D. Chief Medical Officer
Age: 53